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https://doi.org/10.1186/s12876-019-1135-5RESEARCH ARTICLE Open AccessAppraisal of the faecal haemoglobin, age
and sex test (FAST) score in assessment of
patients with lower bowel symptoms: an
observational study
Jayne Digby1, Judith A. Strachan2, Craig Mowat3, Robert J. C. Steele4 and Callum G. Fraser5*Abstract
Background: Many patients present in primary care with lower bowel symptoms, but significant bowel disease
(SBD), comprising colorectal cancer (CRC), advanced adenoma (AA), or inflammatory bowel disease (IBD), is uncommon.
Quantitative faecal immunochemical tests for haemoglobin (FIT), which examine faecal haemoglobin concentrations
(f-Hb), assist in deciding who would benefit from colonoscopy. Incorporation of additional variables in an individual risk-
score might improve this approach. We investigated if the published f-Hb, age and sex test score (FAST score) added
value.
Methods: Data from the first year of routine use of FIT in primary care in one NHS Board in Scotland were examined: f-
Hb was estimated using one HM-JACKarc FIT system (Kyowa Medex Co., Ltd., Tokyo, Japan) with a cut-off for positivity
≥10 μg Hb/g faeces. 5660 specimens were received for analysis in the first year. 4072 patients were referred to secondary
care: 2881 (70.6%) of these had returned a FIT specimen. Of those referred, 1447 had colonoscopy data as well as the f-Hb
result (group A): 2521 patients, also with f-Hb, were not immediately referred (group B). The FAST score was assessed in
both groups.
Results: 1196 (41.7%) of patients who returned a specimen for FIT analysis had f-Hb ≥10 μg Hb/g faeces. In
group A, 252 of 296 (85.1%) with SBD had f-Hb > 10 μg Hb/g faeces, as did 528 of 1151 (45.8%) without SBD.
Using a FAST score > 2.12, which gives high clinical sensitivity for CRC, only 1143 would have been referred
for colonoscopy (21.0% reduction in demand): 286 of 296 (96.6%) with SBD had a positive FAST score, as did
857 of 1151 (74.5%) without SBD. However, one CRC, five AA and four IBD would have been missed. In
group B, although 95.2% had f-Hb < 10 μg Hb/g faeces, 1371 (53.7%) had FAST score ≥ 2.12: clinical rationale
led to only 122 of group B completing subsequent bowel investigations: a FAST score > 2.12 was found in
13 of 15 (86.7%) with SBD.
Conclusions: The performance characteristics of the FAST score did not seem to enhance the utility of f-Hb
alone. Locally-derived formulae might confer desired benefits.
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Faecal immunochemical tests (FIT) for haemoglobin (Hb)
are widely used in opportunistic and programmatic
screening for colorectal cancer (CRC) in asymptomatic
populations [1]. However, most cases of CRC in the
United Kingdom (UK), and probably elsewhere, are diag-
nosed after referral from primary to secondary care [2]. A
difficulty in practice is that very many patients present
with lower bowel symptoms in primary care, but signifi-
cant bowel disease (SBD: colorectal cancer [CRC], ad-
vanced adenoma [AA], sometimes precursors of CRC, or
inflammatory bowel disease [IBD]) is uncommon. Symp-
toms have been well documented to have poor diagnostic
accuracy for SBD [3, 4]. However, the faecal haemoglobin
concentration (f-Hb), as determined by quantitative FIT,
has been proven to be of considerable value in the assess-
ment of symptomatic patients [5–7]. The National Insti-
tute for Health and Care Excellence (NICE) in England
has developed diagnostic guidance (DG30) [8] which
states that: quantitative FIT are recommended for adop-
tion in primary care to guide referral for suspected colo-
rectal cancer in people without rectal bleeding who have
unexplained symptoms but do not meet the criteria for a
suspected cancer pathway referral outlined in NICE’s
guideline on suspected cancer (NG12) [9]. DG30 also
states that results should be reported using a threshold
(cut-off) of 10 μg Hb/g faeces [8]. However, a number of
very real challenges still confound the introduction of FIT
in assessment of patients presenting in primary care with
lower bowel symptoms [10], which include rectal bleeding,
a change in bowel habits, weight loss, anaemia, abdominal
pain and blood in faeces [8].
It has been proposed that prediction or risk-scoring
models, which combine symptoms and/or known risk
factors for SBD with f-Hb, might improve the use of f-
Hb alone [11]. A CRC prediction model, COLONPRE-
DICT, based on both clinical and laboratory findings,
was developed by Cubiella et al., who compared its diag-
nostic accuracy with the 2015 version of the NICE
NG12 referral criteria and externally validated the strat-
egy: it was concluded that COLONPREDICT was a
highly accurate prediction model for CRC detection
[12]. The final prediction model included 11 variables
and, in consequence, we thought that this complexity
might make this approach unlikely to be used in routine
primary care practice. Since we have demonstrated that
f-Hb is affected by age and sex, with f-Hb rising with age
and being higher in men than women [13], an inter-
national multi-centre collaboration led to development
and validation of the FAST score, which combines f-Hb
and age and sex as a single test result which might indi-
cate individual risk of CRC and SBD [14]. The devel-
opers considered that the FAST score was easy to
calculate and was highly accurate for CRC detection insymptomatic patients. Interestingly, the validation cohort
included heterogeneous data from three studies in
Scotland as well as two studies in different regions of
Spain, using a number of different FIT analytical sys-
tems, and it appeared that the FAST score was equally
clinically sensitive for CRC, regardless of country, preva-
lence of disease, age, sex, healthcare level (primary or
secondary) and analytical system used to estimate f-Hb.
However, it was admitted that the diagnostic accuracy
and applicability of the FAST score in a primary care
setting had still to be investigated objectively.
Recently, a comprehensive diagnostic accuracy study
was performed in Spain with data from the 1572 patients
in the COLONPREDICT cohort [15]. The conclusion
was that referral criteria based on f-Hb, used either on
its own or as a component of two prediction models,
COLONPREDICT and the FAST score, are more accur-
ate than symptom-based referral criteria for CRC detec-
tion in patients presenting with lower bowel symptoms.
The symptom-based criteria examined included those
currently used in the UK 2017 update of the NICE
NG12 strategy [9], which was disseminated following
publication of NICE DG30 [8]. However, it is not known
to date whether use of the FAST score, rather than f-Hb
along with clinical impressions and perhaps the use of
other routine tests including the full blood count, would
add value in different geographical settings and using
different criteria for referral for colonoscopy and differ-
ent FIT analytical systems. This study aimed to perform
an initial evaluation of the utility of the FAST score in
patients presenting in primary care for investigation of
lower bowel symptoms, in one region of Scotland, over
the first year of routine use of FIT.
Methods
Data from the first year of routine use of f-Hb in NHS
Tayside, Scotland, were included in our examination of
the use of the FAST score: the full details of the evalu-
ation of the impact of introducing a FIT for into primary
care on the outcome of patients with new bowel symp-
toms have been published [16]. In brief, since December
2015, general practitioners (GP) were encouraged to re-
quest a FIT when evaluating patients presenting with
new lower bowel symptoms. FIT kits, comprising one
specimen collection device (Kyowa Medex Co., Ltd.,
Tokyo, Japan) along with pictorial instructions and a re-
turn envelope, were provided to patients by general
practitioners (GP). When a FIT sample was returned to
the laboratory, f-Hb was estimated using one HM-
JACKarc FIT system (Kyowa Medex). Samples with re-
sults above the upper analytical limit were not diluted
and re-analysed but reported as ≥400 μg Hb/g faeces.
Results with f-Hb < 400 μg Hb/g faeces but ≥10 μg Hb/g
faeces were defined as positive and reported numerically.
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[8]: results < 10 μg Hb/g faeces were reported as f-Hb
not detected. The reports also directed GP to the NHS
Tayside gastroenterology website, which advised that f-
Hb < 10 μg Hb/g faeces, in the absence of iron deficiency
anaemia (IDA), rectal bleeding, or a mass, suggests that
SBD is extremely unlikely. All requests for further inves-
tigation in secondary care were made through a unique
electronic portal. Age and sex were determined from the
Community Health Index (CHI), a unique 10-digit pa-
tient identifier used throughout primary and secondary
care in NHS Scotland.
Five thousand six hundred sixty specimens were re-
ceived in the first year for f-Hb examination (Fig. 1).
Further investigation in secondary care was requested via
the portal for 4072 patients and 2881 of these returned a
specimen for f-Hb examination: at the end of the first
year, 1447 patients had completed a FIT and had under-
gone colonoscopy in secondary care (group A). The utility
of the FAST score was examined in this group A.
2521 patients who had submitted FIT samples were
not associated with an immediate referral. The potential
utility of the FAST score in this group B was also
assessed and outcomes for patients followed for approxi-
mately one further year to assess whether subsequent re-
ferral had occurred and whether SBD had been missed.
In addition, linkage with the Scottish Cancer Registry
was performed to ensure that all cases of CRC had been
identified in both groups A and B.
The FAST score was calculated as detailed earlier using
logistic regression, following a univariate analysis using
generalized additive models with smoothing splines for
continuous variables. Regression coefficients which were
used to construct a CRC prediction score, where the
dependent variable was the presence or absence of CRC
[14]. For f-Hb 0 μg Hb/g faeces, f-Hb score = 0, if f-Hb
from 1 to 19 μg Hb/g faeces, score = 0.684, if f-Hb from 20
to 199 μg Hb/g faeces, score = 2.824 and, if f-Hb > 200 μg
Hb/g faeces, score = 4.184.Then, the FAST score = f-Hb
score + 0.031 x age (years) + 0.479 if male. Interpretation
is: if the FAST score is ≥2.12, there is a high risk of CRC; a
score of < 2.12 implies that there is little risk of CRC and
referral for colonoscopy would be of limited value. The
threshold for the β-coefficient of the FAST score with 99%
clinical sensitivity was 2.12 and was at least that in 88.0%
of the patients included in the derivation cohort.
MedCalc statistical software (MedCalc Software, Mar-
iakerke, Belgium) was used for all calculations. All data
were gathered within routine patient care, therefore eth-
ical approval was not required.
Results
Group A comprised 1447 patients with new bowel
symptoms who completed a FIT and were referred tosecondary care and for whom colonoscopy data, and
histology if required, were available: 780 (53.9%) of these
had f-Hb > 10 μg Hb/g faces. There were 296 with SBD
of whom 252 had a positive f-Hb result (f-Hb > 10 μg
Hb/g faeces) and 1151 without SBD of whom 623 had a
negative f-Hb result (f-Hb < 10 μg Hb/g faeces). Using a
FAST score with > 2.12 as the cut-off so as to give 99%
clinical sensitivity for CRC according to its developers
[14], only 1143 of the 1447 would have been referred for
colonoscopy, a 21.0% reduction in colonoscopy demand.
Of the 296 with SBD, 286 had a positive FAST score. Of
the 1151 without SBD, only 294 had a negative FAST
score. The ten cases detected by f-Hb and other infor-
mation, but not by the FAST score, were one CRC, five
AA and four IBD. Further investigation of referral data
for these cases revealed that the patient with CRC was
referred due to iron deficiency anaemia (IDA). Three of
the five AA reported persistent diarrhoea, one had rectal
bleeding and the remaining AA was a lesion which had
been palpated upon digital rectal examination by the
GP. Of the four cases of IBD associated with a negative
FAST score, two reported rectal bleeding and two had a
change in bowel habit.
The number of colonoscopies required, number (percent-
age) with CRC and SBD, and positive predictive value,
negative predictive value, sensitivity and specificity, with
95% confidence intervals (CI), for both CRC and SBD in
the 1143 patients in group A with FAST score > 2.12 are
shown in Table 1.
Of the 2521 in group B who were not immediately re-
ferred from primary care for colonoscopy, only 4.8% had
f-Hb > 10 μg Hb/g faeces. In marked contrast, 1349
(53.5%) had FAST score ≥ 2.12. The majority of these pa-
tients with negative f-Hb results were not investigated fur-
ther. Indeed, clinical rationale led to only 122 (4.7%) of
these patients ultimately completing bowel investigations.
There were 15 cases of SBD subsequently diagnosed: four
cases of CRC, five cases of AA and six new cases of IBD.
A FAST score ≥ 2.12 was found in 13 (86.7%) of these, in-
cluding all four CRC, which were associated with an initial
f-Hb < 10 μg Hb/g faeces, as were three of the five AA and
three of the six new cases of IBD.
Discussion
The published FAST score was derived from a cohort
consisting of 1572 consecutive symptomatic patients re-
ferred to colonoscopy who were included in the deriv-
ation cohort for the COLONPREDICT study. The
validation cohort included data from three studies done
in Scotland and two in Spain. It was shown that a FAST
score < 2.12 implied that CRC can be ruled out. This
would facilitate the major aim of our use of FIT in as-
sessment of patients presenting with lower bowel symp-
toms, which is as a “rule-out” test, thereby directing the
Table 1 Outcomes for 1143 patients with FAST score > 2.12 in 1447 referred patients with both faecal haemoglobin concentration
and colonoscopy results
Outcome Colorectal cancer (CRC) in the 1143
with FAST score > 2.12
Significant bowel disease (SBD) in the 1143
with FAST score > 2.12
No. of colonoscopies 1143 1143
No (%) with disease 94 (8.2) 286 (25.0)
Positive predictive value (%) with (95% CI) 8.2 (8.0–8.5) 25.0 (24.3–25.8)
Negative predictive value (%) with (95% CI) 98.9 (97.7–100.0) 96.7 (94.1–98.2)
Sensitivity (%) with (95% CI) 99.0 (94.3–100.0) 96.6 (93.9–98.4)
Specificity (%) with (95% CI) 22.4 (20.2–24.7) 25.5 (23.1–28.2)
Fig. 1 Study flow diagram
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those who would benefit most and, more importantly,
reassuring those with a low FAST score that the likeli-
hood of SBD was low. However, safety-netting ap-
proaches, including watching and waiting, should be in
place for those who continue to complain of symptoms
[10]. In addition, it was acknowledged that the patients
included in all of the studies included in the derivation
and validation of the score had been selected a priori by
health care professionals for further evaluation. Further,
it was stated that it was considered that the diagnostic
accuracy of the FAST score should be externally evalu-
ated in patients presenting in primary care with lower
bowel symptoms before its use was extensively adopted.
The recent work of Herrero et al. [15] demonstrated that
88.0% of the 1572 in the COLONPREDICT cohort stud-
ied had a FAST score ≥ 2.12: thus, few (only 12.0%)
would be deemed to have a low risk of CRC and not re-
quire colonoscopy. The clinical sensitivity for the FAST
score > 2.12 was 100.0% (95% CI: 97.8–100.0) and 93.7%
(95% CI: 95.9–98.9) for CRC and SBD respectively, and
the specificity was 13.9% (95% CI: 12.1–15.9) and 16.1%
(95% CI: 14.0–18.4). However, a major caveat is that the
data used, from the COLONPREDICT study, were those
used as the derivation cohort for development of the
FAST score.
In contrast, our analysis of the application of the FAST
score in patients referred from primary care with lower
bowel symptoms, on whom both f-Hb and colonoscopy
data were available, demonstrated that the colonoscopy
demand would be reduced using a FAST score ≥ 2.12
cut-off. The clinical performance characteristics for CRC
and SBD are shown in Table 1. The sensitivity and spe-
cificity in group A were lower and higher, respectively,
from those found in the recent study of Herrero et al. on
the use of the FAST score [15]. This might be because
their group has significant differences to ours, particu-
larly the higher prevalence of CRC and SBD. Eight cases
of SBD would have been missed if the FAST score > 2.12
was used as compared to f-Hb plus clinical data, but
only one case of CRC, which would have been referred
anyway and not missed clinically, since the patient had
IDA. However, a limitation of our study is that group A
had been referred to secondary care without use of the
FAST score: thus, in this study, the use of the FAST
score has actually been examined as a potential follow-
up investigation prior to acceptance into colonoscopy,
assessing whether the score, applied after referral on the
grounds of clinical findings and f-Hb, would lead to a re-
duction in colonoscopies: it does, but a small number of
patients with CRC and SBD would be missed, a less than
ideal finding. Further examination of the cases of SBD
which would be missed if the FAST score had been ap-
plied showed the importance of clinical rationale,because all 15 had what some would term “red flag”
symptoms. However, similar symptoms were also re-
ported by the majority of the remaining 294 referred pa-
tients who also had a negative FAST score, but did not
have SBD; 96 had IDA, 78 had rectal bleeding, 46 had
persistent diarrhoea and 47 had a change in bowel habit.
A prospective study, using the FAST score as the ini-
tial triage tool in routine practice therefore seems to
be warranted from both our data and those of Her-
rero et al. [15]
In those in group B, who were not referred, possibly in
the main because 95.0% had f-Hb < 10 μg Hb/g faeces,
over 50% had a FAST score > 2.12 and thus, if this be-
came the criterion for referral, many more colonoscopies
would be required, without much evidence of the value
of further investigations in this group. One concern,
worthy of further examination, is that the current score
means that all males over 53 years would be referred as
would all females over 68 years and this is the major rea-
son why the score has such high positivity in patients in
group B that were not referred by GP for further investi-
gation. However, clinical rationale led to only 122 (4.7%)
being further investigation over the subsequent year.
Interestingly, despite f-Hb < 10 μg Hb/g faeces, the FAST
score again detected all four CRC found in this group. It
also would have detected all five AA and four out of six
IBD, but the specificity would be very low. A clear limi-
tation of this study is that colonoscopy was not per-
formed on all of group B, but this reflects real routine
practice. Subsequent linkage with the Scottish Cancer
Registry confirmed that all patients with CRC in this
group were identified.
Conclusions
As a result of this study, we cannot support use of the
published FAST score formula [15] to assist in deciding
who to refer for colonoscopy, since SBD was missed in
those who had been referred using f-Hb and other con-
siderations: further, the positivity was more than 50% in
those not referred. In the original development of the
FAST score, it was admitted that a limitation was the re-
duced diagnostic accuracy for detection of not only
CRC, but additional SBD, possibly because the covariate
pattern which predicts CRC may be different to that
which predicts other bowel diseases. On the other hand,
although this reduced accuracy could be considered as a
limitation, there are several cogent arguments to support
use of the FAST score in this broader clinical perspec-
tive [14]. However, we believe that the score could be
improved. One major concern is that the published
score has f-Hb groups based on the analytical perform-
ance characteristics of the OC-Sensor (Eiken Chemical
Co., Ltd., Tokyo, Japan), which has an analytical working
range of 10–200 μg Hb/g faeces, and the 20 μg Hb/g
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ment as the most commonly applied f-Hb cut-off in
CRC screening. We used a different FIT analytical sys-
tem. Albeit that our original development and validation
of the FAST score suggested that there were no inter-
analyser differences [10], we think that a FAST score
with f-Hb groups of < 10, 10–400 and > 400 μg Hb/g fae-
ces should be created for the FIT system most widely
used in the UK for assessment of symptomatic patients
(HM-JACKarc, Kyowa Medex Co., Ltd., Tokyo, Japan):
groups such as this are required because f-Hb does not
have a normal distribution, even after logarithmic trans-
formation, and these groups are used in our and others’
current routine application of FIT in routine practice.
This concept, that different FIT analytical systems may
require different FAST score formulae, is supported by
the results from a recent study [17]. A comparison
showed that the new COLONFIT score, which includes
the maximum f-Hb of three samples and the number of
samples with f-Hb > 4 μg Hb/g faeces in addition to
other variables, classified patients 3–4% better than the
FAST score in both the derivation and validation co-
horts. It was suggested that further studies on a direct
comparison of both scores are needed to assess if the 3–
4% gain in classification could be offset by lower adher-
ence through the requirement for three faecal samples
rather than one. Importantly, however, the FIT analytical
system (iFOB, Linear Chemicals SL, Barcelona, Spain),
which was said to be able to detect f-Hb of 4 μg Hb/g
faeces, was different to that used to derive the FAST
score and that used in this study. The performance of
the FAST score with this FIT analytical system perhaps
could have been improved as suggested above, but with
different and appropriate f-Hb groups.
Moreover, it may be that there is benefit in using
lower f-Hb cut-offs than the 10 μg Hb/g faeces recom-
mended in DG30 [8], for example, using the limit of de-
tection (2 μg Hb/g faeces for the FIT analytical system
used in this study) or the limit of quantitation (7 μg Hb/
g faeces) [18]. Although we have recently suggested that
f-Hb is the most important factor to be considered when
deciding which patients presenting in primary care with
lower bowel symptoms would benefit most from referral
for colonoscopy [19], we plan to create a number of
scores and examine the use of these including lower f-
Hb cut-offs derived from the detectability characteristics
of the FIT system used, which do differ between FIT sys-
tems [18]. Ideally, this should be done prospectively in
our now routine use of FIT in assessment of most pa-
tients presenting in primary care [16], other than those
with rectal bleeding, IDA, or a mass, although the appli-
cation of the FAST score does warrant further study in
such patients, who are currently deemed to be at high
risk. In addition, further risk scores that include f-Hband other variables, should be developed and investi-
gated prospectively.
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